Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
Björn‐Erik Ole Jensen(Düsseldorf University Hospital), Tom Luedde(Düsseldorf University Hospital), David Schoeler(Düsseldorf University Hospital), Nadine Luebke(Düsseldorf University Hospital), Andreas Walker, Ortwin Adams(Heinrich Heine University Düsseldorf), Jörg Timm(Düsseldorf University Hospital), Alexander Dilthey(National Human Genome Research Institute), Rainer Haas(Beth Israel Deaconess Medical Center), Detlef Kindgen‐Milles(Heinrich Heine University Düsseldorf), Matthias Lutterbeck(Düsseldorf University Hospital), Noemi F. Freise(Düsseldorf University Hospital), Verena Keitel(Klinikum Magdeburg), Torsten Feldt(Düsseldorf University Hospital), Timo Brandenburger(Heinrich Heine University Düsseldorf)
Cited by 117
Related Papers
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
|Nature|2011|2.8k
Nanopore sequencing and assembly of a human genome with ultra-long reads
|Nature Biotechnology|2018|2.1k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
|Nature Genetics|2013|1.5k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k